All Posts:Huntington's disease
-
Clinical Research Staff Rise to the Challenges Posed by Pandemic
(July 31, 2020) — Running clinical research can be complicated under normal circumstances but it’s especially arduous during a pandemic. Despite the difficulties, the clinical research teams at Georgetown have worked tirelessly, remotely and on campus, to continue supporting researchers and study participants. “Our team as a whole really stepped up to do this, and […]
Category: GUMC Stories
-
Why Adults at Risk for Huntington’s Disease Choose Not to Learn if They Inherited Deadly Gene
MEDIA CONTACT:Karen Teberkm463@georgetown.edu WASHINGTON (May 16, 2019) — As many as 90 percent of individuals who have a parent with Huntington’s disease (HD) choose not to take a gene test that reveals if they will also develop the fatal disorder — and a new study details the reasons why. Understanding the “why” matters as new […]
Category: News Release
-
Georgetown Physician Leads International Experts in Developing Treatment Guidelines for Huntington’s Disease Symptoms
(February 1, 2019) — A group of international experts in Huntington’s disease, led by Georgetown University Medical Center’s Karen Anderson, MD, has developed consensus guidelines for the clinical management of behavior symptoms caused by the incurable disease. Huntington’s disease is a fatal genetic disorder that impacts a person’s physical and mental abilities that is often accompanied […]
Category: GUMC Stories
-
Doctors Speak Out Panelists on the Progress and Promise of Huntington’s Disease Research
A recent Doctors Speak Out event highlighted the progress scientists have made toward understanding Huntington’s disease, the promise of recent research developments, and the contributions of the Georgetown Huntington’s Disease Care, Education and Research Center (HDCERC).
Category: GUMC Stories
-
Cures Within Reach Funds Huntington’s Disease Clinical Trial with Nilotinib at Georgetown
Georgetown University Medical Center announces a clinical trial testing the safety of the repurposed cancer drug nilotinib in Huntington’s disease. This is the fourth clinical trial of the drug for a neurodegenerative disorder.
Category: News Release